Physician profile
Muhammad Raza
NPI 1619198512
$40,750.76
in general payments reported to CMS, 2019-2025
72 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,603 · 2020: $11K · 2021: $4,859 · 2022: $1,799 · 2023: $4,566 · 2024: $2,280 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,170 · Food and Beverage: $8,432 · Travel and Lodging: $962 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,170.00 |
| Food and Beverage | $8,432.36 |
| Travel and Lodging | $962.11 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $14,802.67 | 2019-2025 | |
| Kite Pharma, INC. | $9,661.89 | 2025 | Yescarta |
| Gilead Sciences, INC. | $1,930.00 | 2020 | |
| Janssen Biotech, INC. | $1,692.26 | 2019-2025 | Carvykti, Talvey, Tecvayli |
| Seagen INC. | $1,520.31 | 2019-2023 | Adcetris, Tukysa |
| Exelixis INC. | $1,470.57 | 2019-2024 | Cabometyx |
| Pfizer INC. | $799.36 | 2019-2025 | |
| Abbvie INC. | $763.63 | 2019-2025 | |
| Celgene Corporation | $723.04 | 2019-2025 | Reblozyl, Onureg, Breyanzi |
| Merck Sharp & Dohme LLC | $453.56 | 2019-2023 | Keytruda, Lenvima, Prevymis |
| Novartis Pharmaceuticals Corporation | $452.30 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $409.88 | 2019-2025 | Opdivo, Krazati, Breyanzi |
| Astrazeneca Pharmaceuticals LP | $398.97 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Daiichi Sankyo INC. | $379.89 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Astellas Pharma US INC | $327.96 | 2019-2025 | Vyloy, Xospata, Padcev |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Raza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.